SREBP‑1 is an independent prognostic marker and promotes invasion and migration in breast cancer

Bao,Jisheng; Zhu,Liping; Zhu,Qi; Su,Jianhua; Liu,Menglan; Huang,Wei

doi:10.3892/ol.2016.4988

SREBP‑1 is an independent prognostic marker and promotes invasion and migration in breast cancer

Authors:
- Jisheng Bao
- Liping Zhu
- Qi Zhu
- Jianhua Su
- Menglan Liu
- Wei Huang
View Affiliations

Affiliations: Department of Geriatrics, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, Jiangsu 214002, P.R. China, Department of Internal Medicine, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, Jiangsu 214002, P.R. China
Published online on: August 10, 2016 https://doi.org/10.3892/ol.2016.4988
Pages: 2409-2416
Copyright: © Bao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Re-programming of lipogenic signaling has been previously demonstrated to result in significant alterations in tumor cell pathology. Sterol regulatory element‑binding protein 1 (SREBP‑1) is a known transcription factor of lipogenic genes. Despite the fact that its functions in proliferation and apoptosis have been elucidated in recent studies, its role in tumor cell migration and invasion, particularly in breast cancer, remains unclear. In present study, the messenger RNA and protein expression levels of SREBP‑1 in cancer tissues were observed to be overexpressed compared with those in matched para‑cancerous tissues (P<0.01). SREBP‑1 level was highly positively correlated with tumor differentiation (P<0.001), tumor‑node‑metastasis stage (P=0.044) and lymph node metastasis (P<0.001). High expression of SREBP‑1 predicted poor prognosis in patients with breast cancer. Additionally, multivariate analysis revealed that SREBP‑1 was an independent factor of 5‑year overall and disease‑specific survival in breast cancer patients (P<0.01). In vitro studies revealed that the suppression of SREBP‑1 expression in both MDA‑MB‑231 and MCF7 cells significantly inhibited cell migration and invasion (P<0.01). The present data indicate that SREBP‑1 plays a critical role in breast cancer migration and invasion, and may serve as a prognostic marker of this malignancy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y and Hortobagyi GN: Is breast cancer survival improving? Cancer. 100:44–52. 2004. View Article : Google Scholar : PubMed/NCBI
3	Hurvitz SA, Hu Y, O'Brien N and Finn RS: Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 39:219–229. 2013. View Article : Google Scholar : PubMed/NCBI
4	Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F and Polyak K: Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 74:1338–1348. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chen J and Gallo KA: MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive metastasis. Cancer Res. 72:4130–4140. 2012. View Article : Google Scholar : PubMed/NCBI
6	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kuhajda FP: Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition. 16:202–208. 2000. View Article : Google Scholar : PubMed/NCBI
8	Puig T, Vázquez-Martin A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J and Colomer R: Fatty acid metabolism in breast cancer cells: Differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat. 109:471–479. 2008. View Article : Google Scholar : PubMed/NCBI
9	Nakakuki M, Shimano H, Inoue N, Tamura M, Matsuzaka T, Nakagawa Y, Yahagi N, Toyoshima H, Sato R and Yamada N: A transcription factor of lipid synthesis, sterol regulatory element-binding protein (SREBP)-1a causes G(1) cell-cycle arrest after accumulation of cyclin-dependent kinase (cdk) inhibitors. FEBS J. 274:4440–4452. 2007. View Article : Google Scholar : PubMed/NCBI
10	Taskinen MR: Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia. 46:733–749. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ruiz R, Jideonwo V, Ahn M, Surendran S, Tagliabracci VS, Hou Y, Gamble A, Kerner J, Irimia-Dominguez JM, Puchowicz MA, et al: Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver. J Biol Chem. 289:5510–5517. 2014. View Article : Google Scholar : PubMed/NCBI
12	Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, et al: EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2:ra822009. View Article : Google Scholar : PubMed/NCBI
13	Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J and Schulze A: PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene. 24:6465–6481. 2005.PubMed/NCBI
14	Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH and Manning BD: Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nie LY, Lu QT, Li WH, Yang N, Dongol S, Zhang X and Jiang J: Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncology Rep. 30:1346–1354. 2013.
16	Guo D, Bell EH and Chakravarti A: Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2:289–299. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, Zhong Z, McCue PA, Sang N, Ji JY, et al: Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 11:2348–2358. 2012. View Article : Google Scholar : PubMed/NCBI
18	Huang WC, Li X, Liu J, Lin J and Chung LW: Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res. 10:133–142. 2012. View Article : Google Scholar : PubMed/NCBI
19	Miyachi K, Sawada Y, Shida Y, Sugawara A and Hisatomi H: Lipogenic gene expression profile in patients with gastric cancer. Mol Clin Oncol. 1:825–827. 2013.PubMed/NCBI
20	Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 100:1369–1372. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H and Zaidi N: De novo lipogenesis in health and disease. Metabolism. 63:895–902. 2014. View Article : Google Scholar : PubMed/NCBI
22	Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, et al: Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 140:1071–1083. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T and Kaneko S: Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 50:100–110. 2009. View Article : Google Scholar : PubMed/NCBI
24	Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W and Verhoeven G: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol. 92:273–279. 2004. View Article : Google Scholar : PubMed/NCBI
25	Song HJ, Sneddon AA, Heys SD and Wahle KW: Regulation of fatty acid synthase (FAS) and apoptosis in estrogen-receptor positive and negative breast cancer cells by conjugated linoleic acids. Prostaglandins Leukot Essent Fatty Acids. 87:197–203. 2012. View Article : Google Scholar : PubMed/NCBI
26	Lee JS, Sul JY, Park JB, Lee MS, Cha EY, Song IS, Kim JR and Chang ES: Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells. Phytother Res. 27:713–720. 2013. View Article : Google Scholar : PubMed/NCBI
27	Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, et al: Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res. 9:1551–1561. 2011. View Article : Google Scholar : PubMed/NCBI
28	Tong L and Harwood HJ Jr: Acetyl-coenzyme A carboxylases: Versatile targets for drug discovery. J Cell Biochem. 99:1476–1488. 2006. View Article : Google Scholar : PubMed/NCBI